IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i7p4069-d782483.html
   My bibliography  Save this article

Cystic Fibrosis-Related Diabetes in Poland

Author

Listed:
  • Marta Rachel

    (Institute of Medical Sciences, Medical College, Rzeszów University, Warzywna 1a, 35-310 Rzeszów, Poland
    Department of Allergology and Cystic Fibrosis, State Hospital 2 in Rzeszow, Lwowska 60, 35-301 Rzeszów, Poland)

  • Marek Biesiadecki

    (Institute of Medical Sciences, Medical College, Rzeszów University, Warzywna 1a, 35-310 Rzeszów, Poland)

  • Sabina Galiniak

    (Institute of Medical Sciences, Medical College, Rzeszów University, Warzywna 1a, 35-310 Rzeszów, Poland)

Abstract

Cystic fibrosis (CF) is the most common autosomal recessive inherited monogenic disease in Caucasians. As medical technology progresses and the quality of patient care improves, the survival time of patients with CF has increased, which results in more frequent comorbidities such as cystic fibrosis-related diabetes (CFRD). CFRD is the result of abnormal glucose metabolism characterized primarily by insulin deficiency, exacerbated periodically by insulin resistance. The aim of our study was to analyze the epidemiology of patients with CFRD in Poland on the basis of data collected from six CF treatment centers. Analyses were performed on 1157 CF patients who were treated at one of the six CF care centers. CFRD was diagnosed according to standard criteria. All data including demographics, types of CFTR mutations, CFRD duration, and microorganisms in the sputum were obtained from the patients’ medical history. Our study indicates that the prevalence of CFRD in Poland is 12.9%. CFRD was most often diagnosed between the ages of 11 and 20 (60% of patients), while 23% of patients were diagnosed between 21 and 30 years of age. Furthermore, we observed that approximately 3–5% of patients under the age of 10 had CFRD. We found out that the type of mutation did not affect the frequency of CFRD development. Factors that increased the risk of developing CFRD include underweight and chronic Pseudomonas aeruginosa infection. Due to the extended lifespan of CF patients, the number of CFRD patients is currently increasing. We believe that the results of our study may complement information from other studies or may be useful in planning health policy in Poland.

Suggested Citation

  • Marta Rachel & Marek Biesiadecki & Sabina Galiniak, 2022. "Cystic Fibrosis-Related Diabetes in Poland," IJERPH, MDPI, vol. 19(7), pages 1-9, March.
  • Handle: RePEc:gam:jijerp:v:19:y:2022:i:7:p:4069-:d:782483
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/7/4069/pdf
    Download Restriction: no

    File URL: https://www.mdpi.com/1660-4601/19/7/4069/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Marta Rachel & Stanisław Topolewicz & Andrzej Śliwczyński & Sabina Galiniak, 2020. "Managing Cystic Fibrosis in Polish Healthcare," IJERPH, MDPI, vol. 17(20), pages 1-17, October.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Thi Tham Nguyen & Congrong He & Robyn Carter & Emma L. Ballard & Kim Smith & Robert Groth & Esa Jaatinen & Timothy J. Kidd & Thuy-Khanh Nguyen & Rebecca E. Stockwell & George Tay & Graham R. Johnson &, 2022. "The Effectiveness of Ultraviolet-C (UV-C) Irradiation on the Viability of Airborne Pseudomonas aeruginosa," IJERPH, MDPI, vol. 19(20), pages 1-15, October.
    2. Marta Rachel & Sabina Galiniak & Marek Biesiadecki & Agnieszka Gala-Błądzińska, 2022. "Renal Function in Patients with Cystic Fibrosis: A Single-Center Study," IJERPH, MDPI, vol. 19(9), pages 1-11, April.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:7:p:4069-:d:782483. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.